Days
Hours
Minutes
Seconds
-40%
on all subscriptions*
Exceptional extension!
Enjoy this offer
* See conditions under "Our services"
12/05 Alexion Reports Positive CALYPSO Phase III Trial Results For Eneboparatide In Adults With Hypoparathyroidism CI
04/12 Neurimmune Expands Collaboration with Alexion to Develop and Commercialize Fibril Depleter NI009 for AL Amyloidosis CI
20/11 Alexion, AstraZeneca Rare Disease's Koselugo (selumetinib) Approves in the US CI
12/24/12 Alexion, AstraZeneca Rare Disease and Merck Announces Positive Topline Results from the Phase 3 Komet Trial CI
25/24/25 Monopar Therapeutics Inc. acquired worldwide license to ALXN-18 from Alexion Pharmaceuticals, Inc. for approximately $110 million. CI
24/24/24 Monopar Therapeutics Inc Announces Agreement with Alexion, AstraZeneca Rare Disease for Late-Stage Wilson Disease Drug Candidate CI
01/24/01 Alexion Pharmaceuticals, Inc.'s VOYDEYA Receives Approval in US Add-On Therapy to Ravulizumab or Eculizumab for Treatment of Extravascular Hemolysis in Adults with the Rare Disease PNH CI
11/23/11 Alexion Announces Long-Term Alpha Phase III Trial Data Shows Danicopan as Add-On to Standard of Care C5 Inhibitor Therapy ULTOMIRIS CI
19/23/19 Alexion Pharmaceuticals, Inc. completed the acquisition of Assets of early-stage rare disease gene therapy portfolio of Pfizer Inc.. CI
08/23/08 Verge Genomics Announces Artificial Intelligence-Enabled Drug Discovery Collaboration with Alexion for Rare Neurodegenerative and Neuromuscular Diseases CI
28/23/28 Alexion Pharmaceuticals, Inc. entered a definitive purchase agreement to acquire Assets of early-stage rare disease gene therapy portfolio of Pfizer Inc. for $1 billion. CI
30/23/30 JCR Pharmaceuticals Co., Ltd. Announces Research Collaboration, Option and License Agreement with Alexion to Develop a Therapy Using J-Brain CargoR for Neurodegenerative Disease CI
15/22/15 Alexion Pharmaceuticals, Inc. completed the acquisition of LogicBio Therapeutics, Inc. from a group of shareholders. CI
Manager TitleAgeSince
Chief Executive Officer 73 -
Director of Finance/CFO 53 01/08/2021
Chief Operating Officer - -
Date Insider Type Main position Quantity % Market Cap.
21/21/21Issuer sale

Director

14,629 0.0066%
21/21/21Issuer sale

EVP & CCAO

59,226 0.0268%
21/21/21Issuer sale

Director

42,193 0.0191%
Change 5-day change 1-year change 3-year change Capi.($)
+1.70%-2.20% - - 4.03TCr
+0.32%-2.73%+44.49%+143.28% 98TCr
+1.27%-3.98%+54.41%+41.13% 55TCr
+6.25%+1.00%+24.13%+68.06% 38TCr
+0.25%-3.09%+23.33%+16.78% 32TCr
+0.42%-1.28%+27.89%+14.71% 27TCr
+1.67%-1.47%+26.76%+32.88% 27TCr
+2.39%+4.42%-36.96%-45.12% 20TCr
+2.11%-2.95%+19.14%+51.83% 18TCr
+0.90%-0.57%+15.09%+60.89% 15TCr
Average +1.73%-2.70%+22.03%+42.72% 36.69TCr
Weighted average by Cap. +1.53%-3.50%+31.28%+65.69%
Logo Alexion Pharmaceuticals, Inc.
Alexion Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on discovering, development and commercialization of medicines. The Company's marketed products include ULTOMIRIS, SOLIRIS (eculizumab), STRENSIQ (asfotase alfa), KANUMA (sebelipase alfa) and ANDEXXA (coagulation Factor Xa - [recombinant] inactivated-zhzo). Its ULTOMIRIS product is a long-acting C5 inhibitor, that works by inhibiting the C5 protein in the terminal complement cascade. Its SOLIRIS product is a humanized monoclonal antibody that blocks terminal activity at the doses prescribed. Its Strensiq product is a targeted enzyme replacement therapy for patients with Hypophosphatasia (HPP). Its Kanuma product is a recombinant form of the human lysosomal acid lipase (LAL) enzyme. Its ANDEXXA product is a reversal agent for patients treated with rivaroxaban or apixaban.
Employees
3,837
  1. Stock Market
  2. Stocks
  3. ALXN Stock
-40%: Exceptional extension
d
:
:
SEIZE THE OFFER!